# A Pill to Hold What the Injection Lost

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/a-pill-to-hold-what-the-injection-lost

> Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.

## Key points

- Weight reduction maintained at 52 weeks: 79.3% vs 37.6% after semaglutide, 74.7% vs 49.2% after tirzepatide.
- No arm continued the injection, so it beats stopping, and may or may not match staying.
- Placebo still held 37.6% to 49.2% at a year: a third data point against 'you regain everything'.
- A small molecule scales in manufacturing where injectable peptides do not.

Plenty of people would like to lose the weight on an injection and then hold it with something simpler. A phase 3b trial tested that handover: participants who had lost weight on injectable semaglutide or tirzepatide moved to daily oral orforglipron or to placebo. In those coming off semaglutide, the pill maintained **79.3%** of the reduction against **37.6%** on placebo at 52 weeks. In those coming off tirzepatide, the figures were 74.7% against 49.2%.[1]

## The result

In the semaglutide group the estimated treatment difference was 41.7 percentage points, with a confidence interval from 24.4 to 59.0. That is a wide interval, but comfortably clear of zero. In the tirzepatide group the difference was 25.5 points. All key secondary endpoints were met. The commonest adverse events were gastrointestinal and mostly mild to moderate.[1]

The placebo figure deserves its own look. People who switched to nothing still held 37.6% (after semaglutide) or 49.2% (after tirzepatide) of what they had lost, at a year. That is a third data point, after the [real-world discontinuation data](https://glpwatchdog.org/research/what-people-actually-do-after-stopping) and SURMOUNT-4’s placebo arm, against the popular account that stopping means regaining everything.

## The comparison that was not run

> There was no arm that stayed on the injection.

The authors name this limitation themselves.[1] It matters more than any figure in the trial, because it is the question people have. Nobody wonders whether a pill beats stopping; obviously it does. What they want to know is whether switching costs them anything against staying on what was working.

We have one adjacent answer. In SURMOUNT-MAINTAIN, people who *stepped down* to a lower injectable dose held less than those who stayed at full dose, and needed rescue therapy three times as often (25% against 8%; see [the maintenance trial](https://glpwatchdog.org/research/tirzepatide-maintenance-dose-trial)). Less drug held much of the loss, but measurably less of it. Whether a switch to an oral agent behaves the same way is untested.

> **The trial is also only a year long**, which the authors note. Maintenance is a question about years, and a 52-week answer to it is a beginning. Three other ways of using less drug ([a lower labeled dose](https://glpwatchdog.org/research/what-a-low-dose-actually-does), a longer interval, a sub-labeled microdose) are set out in [every other week](https://glpwatchdog.org/research/every-other-week-dosing). Switching to a different drug entirely is now a fourth.

## Why an oral maintenance option matters commercially

The authors describe orforglipron as a potentially globally scalable option, and scalability is the point. Orforglipron is a small molecule rather than a peptide, so it can be manufactured at a scale injectable peptides cannot. Peptide manufacturing capacity is the constraint behind the shortages this register has tracked from the commercial end.

A world where the expensive, supply-constrained injectable does the losing and a manufacturable pill does the holding is a plausible answer to a real bottleneck. It is also a commercially convenient story. Watch whether the maintenance data ever gets a fair comparison against simply continuing.

## Frequently asked questions

### Can you switch from an injection to a pill to maintain weight loss?

A phase 3b trial found daily oral orforglipron maintained 79.3% of the weight already lost against 37.6% on placebo at 52 weeks in people coming off semaglutide, and 74.7% against 49.2% in people coming off tirzepatide. It tested that handover directly, in a randomized trial.

### Is the pill as good as staying on the injection?

Unknown, and this trial cannot say, because there was no arm that continued injectable therapy. The authors list that as a limitation. It is also the question most people want answered.

### What happened to people who switched to nothing?

They held 37.6% (after semaglutide) or 49.2% (after tirzepatide) of the weight they had lost at one year. That is another data point against the idea that stopping means regaining everything, though it is clearly worse than continuing on something.

### How long was this tested for?

One year, which the authors also flag. Maintenance is a question about years, so a 52-week result is a starting point rather than a settled answer.

### Why does an oral option matter beyond convenience?

Because it is a small molecule rather than a peptide, so it can be manufactured at far greater scale. That bears directly on the supply constraints that have shaped this market.

## References

1. Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026. PMID: 42120723. https://pubmed.ncbi.nlm.nih.gov/42120723/

---

Cite as: GLP Watchdog, Nora Bissett, "A Pill to Hold What the Injection Lost", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/a-pill-to-hold-what-the-injection-lost

Canonical HTML page: https://glpwatchdog.org/research/a-pill-to-hold-what-the-injection-lost

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
